level has a negative relationship with serum IgA level

S387

J Clin Immunol (2014) 34 (Suppl 2):S139–S515

level has a negative relationship with serum IgA level (r=-0.06) and IVIg treatment duration (r=-0.006). Conclusion: There was a significant correlation between antiIgA antibody presence and the adverse reactions, especially in CVID patients with higher susceptibility to produce this constitutional antibody. Keywords: Anti IgA, Adverse reaction, Common variable immunodeficiency, Intravenous immunoglobulin

ESID-0388 The Clinical Effectiveness of Immunoglobulin Infusion Therapy in Specific Antibody Deficiency (SAD) H. Alachkar1, M. Arslan Anwar2 1

Immunology, Salford Royal Hospital, Manchester, United Kingdom 2 Medical School, Manchester University, Manchester, United Kingdom SAD is the most frequently diagnosed PID, characterized by an impaired response to polysaccharide antigens/vaccines with normal immunoglobulin levels. Patients are susceptible to sinopulmonary infections with polysaccharide encapsulated bacteria. The recurrent infections may lead to bronchiectasis and chronic sinus disease. Immunoglobulin infusion is one of treatment options for SAD. The aim of this study was to assess the clinical effectiveness of immunoglobulin infusion therapy in SAD patients. Methods- Retrospective data collection. We looked at age of diagnosis, delay in diagnosis, occurrence of pneumonia and respiratory comorbidities (COPD, asthma, and bronchiectasis). The outcome measures were: number of chest infections and hospital admissions per year after immunoglobulin therapy started and patient’s perception of well-being. Results- we identified 45 patients (70% females), who fulfilled the criteria of “isolated” SAD diagnosis. Two groups were recognized according to the number of infections after starting treatment; Group 1 (G1=25 patients) continued to have ≥3 respiratory infection per year (mean of 4.4), and Group 2 (G2=20) had